| Literature DB >> 27111394 |
Hongmiao Sun1, Xinping Zhong2, Chunyu Wang1, Shengli Wang1, Lin Lin1, Renlong Zou1, Yi Wu1, Ning Sun1, Ge Sun1, Tao Wen1, Zhi-Hong Chi3, Yue Zhao1.
Abstract
SNF5 (SMARCB1/INI1/BAF47), a core subunit of SWI/SNF complex, has been reported to modulate cell proliferation and apoptosis. Genetic evidence has suggested that SNF5 participates in tumor suppression. However, the detailed biological function and underlying mechanisms of SNF5 in hepatocellular carcinoma (HCC) progression remain unclear. Here, SNF5 expression reduction in HCC tissues compared with the adjacent non-cancerous tissues has been demonstrated. Importantly, the results showed that reduced SNF5 expression has a strong correlation with worse overall survival of HCC patients. The data demonstrated that knockdown of SNF5 significantly promoted cell growth and migration in Hep3B and HCCLM3 cell lines. Interestingly, it was found that SNF5 suppressed transforming growth factor-β1 (TGF-β1) expression, and SNF5 mRNA expression was negatively correlated with TGF-β1 in HCC tissues. Furthermore, depletion of SNF5 attenuated the sensitivity of HCC cells to sorafenib. Thus, the data suggested that SNF5 may participate in HCC suppression, and reduced expression of SNF5 correlates with the poor differentiation and prognosis of HCC, indicating that SNF5 might be an important prognostic biomarker and promising therapeutic target for HCC. Anat Rec, 299:869-877, 2016.Entities:
Keywords: SNF5; TGF-β1; hepatocellular carcinoma; sorafenib; tumor suppression
Mesh:
Substances:
Year: 2016 PMID: 27111394 DOI: 10.1002/ar.23357
Source DB: PubMed Journal: Anat Rec (Hoboken) ISSN: 1932-8486 Impact factor: 2.064